血浆内源性阿片肽与肝硬化门脉血流动力学的关系  

Role of endogenous opioid peptides on portal hypertension in cirrhosis

作　　者：李学文 王成海[2] 

机构地区：[1]解放军第一六三中心医院消化科,湖南长沙410003 [2]第二军医大学神经生物教研室

出　　处：《中国医师杂志》2006年第10期1329-1330,共2页Journal of Chinese Physician

摘　　要：目的探索肝硬化门脉高压患者血浆DynA1-13和L-ENK与门脉血流动力学的关系。方法检测肝硬化患者及正常人的血浆DynA1-13和L-ENK,同时彩超记录门脉宽度、血流量和流速。结果肝硬化患者血浆DynA1-13和L-ENK浓度均明显高于正常对照组,随门脉压力的增高,DynA1-13和L-ENK均呈上升趋势。肝硬化患者门脉宽度、血流量和流速均与正常对照组差异有统计学意义,相关分析表明:在门脉宽度≥12 mm组,血浆DynA1-13、L-ENK与门脉宽度、血流量及流速之间均呈正相关。结论血浆DynA1-13和L-ENK不仅反映肝硬化的严重程度,并且可反映肝硬化门脉高压的血流动力学改变。Objective To assess the relationship between endogenous opioid peptides and hemodynamic of portal hytertension in cirrhosis. Methods L-ENK and DynA1 -13 were measured in plasma samples collected from 48 patients with cirrhosis and 30 healthy controls. Results Plasma L- ENK and DynA1-13 in cirrhosis patients were significantly higher than those of healthy controls; L-ENK and DynA1-13 levels in patients with portal width≥12mm were in correlation with the portal width, blood flow and velocity . Conclusion The increased levels of L-ENK and DynA1-13 are important indexes for portal hypertension in cirrhosis.

关 键 词：阿片样肽类/血液 肝硬化 门脉系统 

分 类 号：R575.2[医药卫生—消化系统]